Subtype Spec.& Arrhythmogenica Potential of Stem Cell Derived Cardiomyocytes

$515,801P01FY2011HLNIH

University Of Washington, Seattle WA

Investigators

Linked publications & trials

Paper 32426414 Paper 31945113 Paper 31723070 Paper 31587567 Paper 31564645 Paper 31375810 Paper 31049579 Paper 30587544 Paper 30566022 Paper 30190531 Paper 29969440 Paper 29942806 Paper 29888752 Paper 28813672 Paper 28684531 Paper 28562232 Paper 28553667 Paper 28483831 Paper 28065644 Paper 27906170 Paper 27737958 Paper 27716639 Paper 27600722 Paper 27503462 Paper 27161364 Paper 26955856 Paper 26866596 Paper 26807015 Paper 26755607 Paper 26607951 Paper 26487784 Paper 26395136 Paper 26388461 Paper 26269526 Paper 26161513 Paper 26153229 Paper 26076956 Paper 25980938 Paper 25978043 Paper 25964336 Paper 25865043 Paper 25795463 Paper 25342771 Paper 25290689 Paper 25093889 Paper 25087896 Paper 25070341 Paper 24838687 Paper 24819474 Paper 24780238 Paper 24776797 Paper 24735830 Paper 24687990 Paper 24685664 Paper 24672751 Paper 24628277 Paper 24615475 Paper 24516260 Paper 24481842 Paper 24141057 Paper 24131213 Paper 24127199 Paper 24118766 Paper 24090675 Paper 23959984 Paper 23953118 Paper 23924634 Paper 23911435 Paper 23793239 Paper 23723253 Paper 23722092 Paper 23637832 Paper 23530224 Paper 23520463 Paper 23517131 Paper 23463965 Paper 23461462 Paper 23448137 Paper 23391309 Paper 23071682 Paper 22981225 Paper 22864415 Paper 22660313 Paper 22512900 Paper 22400029 Paper 22362654 Paper 22353785 Paper 21925507 Paper 21886766 Paper 21822893 Paper 21597009 Paper 21593865 Paper 21474095 Paper 21293854 Paper 21211785 Paper 21187004 Paper 21186056 Paper 21084757 Paper 20854826 Paper 20696917

Abstract

Project 2: Subtype Specification and Arrhythmogenic Potential of Stem Cell Derived Cardiomyocytes. Cardiomyocytes derived from human embryonic stem cells (hESCs) have tremendous promise for cardiac repair, both for replacing ventricular myocardium after an infarct and serving as a "biologic pacemaker" in diseases like sick-sinus syndrome. We have reported methods to generate large quantities of highly purified cardiomyocytes from hESCs, but these preparations include cells with distinct nodal/pacemaker and "working" (i.e. chamber-like) phenotypes. For these cells to be useful and safe, they must have electrophysiological properties matched to each application. Hence, this project will develop approaches to control the cardiac subtype of hESC derivatives and then will determine their electrophysiological behavior following transplantation in intact and infarcted hearts. In Aim 1, we will develop a genetic selection system to follow the lineage relationships of cardiac subtypes derived from hESCs. This work builds on our preliminary findings that a promoter element from the cGATA6 gene identifies hESC-derived cardiomyocytes with the nodal phenotype. In Aim 2, we will elucidate the molecular events by which neuregulin/ErbB signaling regulates the cardiac subtype of hESC-derived cardion\yocytes. This work will employ the genetic reporters from Aim 1 but will also lead to complementary pharmacological approaches to control cardiac subtype specification. In Aim 3, we will address two uncertainties regarding the electrophysiological behavior of hESC-derived cardiomyocytes following transplantation. First, we will test whether these cells are electrically coupled and beat synchronously with host muscle in normal and infarcted hearts. Second, we will test the hypothesis that their transplantation will modulate the incidence of infarct-related arrhythmias, while the incidence of graft-associated arrhythmias can be "tuned" by controlling the phenotype of the input cell preparation.

View original record on NIH RePORTER →